

UCDH ANTIBIOGRAM

01/01/2019 - 12/31/2019

PERCENT OF ISOLATES SUSCEPTIBLE

Anna Maria Romanelli, Ph.D.

Director, Clinical Microbiology Laboratory

PEDIATRIC Inpatient ICU - Gram Negative Organisms

Category		Beta-lactams									Fluoro quino lones		Amino glycosides			Other	
Organism	n	Ampicillin	Ampicillin/ Sulbactam	Piperacillin/ Tazobactam	Cefazolin	Ceftazidime	Ceftriaxone	Cefepime	Aztreonam	Meropenem	Ciprofloxacin	Levofloxacin	Amikacin	Gentamicin	Tobramycin	Trimethoprim/ Sulfamethoxazole	Nitrofurantoin
breakpoints (mcg/mL)		8	8/4	16/4	2	4	1	2	4	1	1	2	16	4	4	2/38	32
Escherichia coli	28 ^A	17	7	96	60	89	89	89	89	100	85	85	100	73	75	50	93
Klebsiella oxytoca	10 ^A	0	50	100	10	100	100	100	100	100	100	100	100	100	100	100	100
Klebsiella pneumoniae	15 ^A	0	100	86	80	86	93	86	93	100	80	93	100	85	86	80	25
breakpoints (mcg/mL)				16/4		8		8	8	2	1	2	16	4	4		
Pseudomonas aeruginosa	22 ^A	-	-	95	-	90	-	90	76	95	86	81	100	94	95	-	-
breakpoints (mcg/mL)						8						2				2/38	
Stenotrophomonas maltophilia	12 ^A	-	-	-	-	25	-	0	-	0	-	75	-	-	-	100	-

PEDIATRIC Inpatient Non-ICU - Gram Negative Organisms

Category		Beta-lactams									Fluoro quino lones		Amino glycosides			Other	
Organism	n	Ampicillin	Ampicillin/ Sulbactam	Piperacillin/ Tazobactam	Cefazolin	Ceftazidime	Ceftriaxone	Cefepime	Aztreonam	Meropenem	Ciprofloxacin	Levofloxacin	Amikacin	Gentamicin	Tobramycin	Trimethoprim/ Sulfamethoxazole	Nitrofurantoin
breakpoints (mcg/mL)		8	8/4	16/4	2	4	1	2	4	1	1	2	16	4	4	2/38	32
Escherichia coli	28 ^A	35	33	92	57	82	85	85	82	100	82	82	100	92	92	64	100
Klebsiella pneumoniae	7 ^A	0	100	85	85	85	85	85	85	100	85	100	100	83	85	57	33
breakpoints (mcg/mL)				16/4		8		8	8	2	1	2	16	4	4		
Pseudomonas aeruginosa	14 ^A	-	-	92	-	92	-	92	78	100	100	100	100	100	100	-	-

UCDH ANTIBIOGRAM

01/01/2019 - 12/31/2019

PERCENT OF ISOLATES SUSCEPTIBLE

Anna Maria Romanelli, Ph.D.

Director, Clinical Microbiology Laboratory

PEDIATRIC Outpatient / ED - Gram Negative Organisms

Category	n	Beta-lactams									Fluoro quinolones		Amino glycosides			Other	
		Ampicillin	Ampicillin/ Sulbactam	Piperacillin/ Tazobactam	Cefazolin	Ceftazidime	Ceftriaxone	Cefepime	Aztreonam	Meropenem	Ciprofloxacin	Levofloxacin	Amikacin	Gentamicin	Tobramycin	Trimethoprim/ Sulfamethoxazole	Nitrofurantoin
breakpoints (mcg/mL)		8	8/4	16/4	2	4	1	2	4	1	1	2	16	4	4	2/38	32
Citrobacter freundii complex	9 ^A	0	0	88	0	88	88	88	88	100	100	100	100	83	77	100	83
Enterobacter cloacae complex	15 ^A	0	0	80	0	80	80	93	80	93	93	100	100	100	93	100	11
Escherichia coli	296	60	80	98	76	94	94	95	94	100	90	93	100	93	92	77	99
Klebsiella oxytoca	16 ^A	0	40	100	6	100	100	100	100	100	100	100	100	100	100	100	91
Klebsiella pneumoniae	24 ^A	0	50	79	75	87	87	83	87	100	83	95	95	86	87	83	60
Proteus mirabilis	10 ^A	80	-	100	0	100	100	100	100	100	90	100	100	80	80	80	0
breakpoints (mcg/mL)				16/4		8		8	8	2	1	2	16	4	4		
Pseudomonas aeruginosa	43	-	-	95	-	97	-	95	79	95	86	83	95	94	100	-	-

Data source: UCDH Laboratory Information Service, excluding duplicate, CF and surveillance isolates.

Breakpoints for susceptibility defined by Clinical Laboratory Standards Institute (CLSI M100 28th Edition, Jan 2018) .

Breakpoint values in red are values that are different from the 2018 AntibioGram which was based on CLSI M100 20th Ed, Jan 2010.

Organisms with a total number of less than 10 isolates recovered for the year are not included in this report with some exceptions.

≥10% increase in % of susceptible isolates compared to 2018

≥10% decrease in % susceptible isolates compared to 2018

Footnote

A Calculated from fewer than the standard recommendation of 30 isolates. Interpret with caution.